AgomAb Therapeutics (NASDAQ:AGMB) CEO Tim Jasper Knotnerus Buys 5,000 Shares of Stock

AgomAb Therapeutics NV (NASDAQ:AGMB) CEO Tim Jasper Knotnerus acquired 5,000 shares of the stock in a transaction that occurred on Tuesday, October 6th. The shares were bought at an average price of $8.70 per share, for a total transaction of $43,500.00. Following the purchase, the chief executive officer directly owned 21,823 shares of the company’s stock, valued at approximately $189,860.10. This trade represents a 29.72% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Tim Jasper Knotnerus also recently made the following trade(s):

• On Monday, October 5th, Tim Jasper Knotnerus purchased 6,000 shares of AgomAb Therapeutics stock. The shares were purchased at an average price of $8.48 per share, for a total transaction of $50,880.00.

AgomAb Therapeutics Price Performance

AGMB opened at $8.84 on Wednesday. The stock’s fifty day moving average is $12.82 and its 200-day moving average is $12.00. AgomAb Therapeutics NV has a one year low of $7.97 and a one year high of $17.82.

AgomAb Therapeutics (NASDAQ:AGMB) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.46) earnings per share for the quarter. As a group, equities research analysts predict that AgomAb Therapeutics NV will post -1.76 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on AGMB shares. Piper Sandler initiated coverage on shares of AgomAb Therapeutics in a research report on Tuesday, August 25th. They issued an “overweight” rating and a $60.00 price target on the stock. HC Wainwright restated a “buy” rating on shares of AgomAb Therapeutics in a report on Wednesday, September 16th. Wall Street Zen lowered AgomAb Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, September 27th. Cantor Fitzgerald initiated coverage on AgomAb Therapeutics in a report on Wednesday, August 19th. They set an “overweight” rating for the company. Finally, B. Riley Financial started coverage on AgomAb Therapeutics in a research report on Thursday, July 23rd. They issued a “buy” rating and a $34.00 price target for the company. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $37.50.

AgomAb Therapeutics Company Profile

Agomab Therapeutics N.V. is a clinical-stage biotechnology company developing antibody-based medicines designed to activate biological pathways involved in tissue repair and regeneration. The company focuses on serious diseases in which restoring or rebuilding damaged tissue could provide therapeutic benefit.

Agomab’s lead program, AGMB-129, is an investigational, gut-restricted agonist of fibroblast growth factor receptor 1c (FGFR1c) being developed for inflammatory bowel disease, including Crohn’s disease.